The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways

Biochemical and Biophysical Research Communications

Volumn 456, Issue 3, 2015, Pages 757-762

  Tréhoux, Solange ^b   Duchêne, Bélinda ^b   Jonckheere, Nicolas ^b   Van Seuningen, Isabelle ^a  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b UNIV LILLE   (France)

Author keywords

Chemoresistance; Invasion; Migration; MUC1; Pancreatic cancer; Proliferation

Indexed keywords

COLLAGENASE 3; FLUOROURACIL; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUC1 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE; TUMOR INVASION;

MUS;

ANIMALS; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; MATRIX METALLOPROTEINASE 13; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUCIN-1; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84920731725     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.12.025     Document Type: Article

References (25)

1. N. Jonckheere, and I. Van Seuningen The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies Crit. Rev. Oncog. 14 2008 177 196
2. M.A. Hollingsworth, and B.J. Swanson Mucins in cancer: protection and control of the cell surface Nat. Rev. Cancer 4 2004 45 60 10.1038/nrc1251
3. D.W. Kufe Mucins in cancer: function, prognosis and therapy Nat. Rev. Cancer 9 2009 874 885 10.1038/nrc2761
4. N. Jonckheere, and I. Van Seuningen The membrane-bound mucins: from cell signalling to transcriptional regulation and expression in epithelial cancers Biochimie 92 2010 1 11 10.1016/j.biochi.2009.09.018
5. J.A. Schroeder, M.C. Thompson, M.M. Gardner, and S.J. Gendler Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland J. Biol. Chem. 276 2001 13057 13064 10.1074/jbc.M011248200
6. J.A. Schroeder, M.C. Adriance, M.C. Thompson, T.D. Camenisch, and S.J. Gendler MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion Oncogene 22 2003 1324 1332 10.1038/sj.onc.1206291
7. D. Raina, S. Kharbanda, and D. Kufe The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts J. Biol. Chem. 279 2004 20607 20612 10.1074/jbc.M310538200
8. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J. Clin. 63 2013 11 30 10.3322/caac.21166
9. A. Vincent, J. Herman, R. Schulick, R.H. Hruban, and M. Goggins Pancreatic cancer Lancet 378 2011 607 620 10.1016/S0140-6736(10)62307-0
10. T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, and Y. Bécouarn FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N. Engl. J. Med. 364 2011 1817 1825 10.1056/NEJMoa1011923
11. J.M. Winter, L.H. Tang, D.S. Klimstra, M.F. Brennan, J.R. Brody, and F.G. Rocha A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers PLoS One 7 2012 e40157 10.1371/journal.pone.0040157
12. R.E. Beatson, J. Taylor-Papadimitriou, and J.M. Burchell MUC1 immunotherapy Immunotherapy 2 2010 305 327 10.2217/imt.10.17
13. L.D. Roy, M. Sahraei, D.B. Subramani, D. Besmer, S. Nath, and T.L. Tinder MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition Oncogene 30 2011 1449 1459 10.1038/onc.2010.526
14. S. Nath, K. Daneshvar, L.D. Roy, P. Grover, A. Kidiyoor, and L. Mosley MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes Oncogenesis 2 2013 e51 10.1038/oncsis.2013.16
15. J. Gao, M.J. McConnell, B. Yu, J. Li, J.M. Balko, and E.P. Black MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion Int. J. Oncol. 35 2009 337 345
16. P.K. Singh, Y. Wen, B.J. Swanson, K. Shanmugam, A. Kazlauskas, and R.L. Cerny Platelet-derived growth factor receptor β-mediated phosphorylation of muc1 enhances invasiveness in pancreatic adenocarcinoma cells Cancer Res. 67 2007 5201 5210 10.1158/0008-5472.CAN-06-4647
17. N. Skrypek, B. Duchêne, M. Hebbar, E. Leteurtre, I. van Seuningen, and N. Jonckheere The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the concentrative nucleoside transporter family Oncogene 32 2013 1714 1723 10.1038/onc.2012.179
18. C. Gronnier, E. Bruyère, F. Lahdaoui, N. Jonckheere, M. Perrais, and E. Leteurtre The MUC1 mucin regulates the tumorigenic properties of human esophageal adenocarcinomatous cells Biochim. Biophys. Acta-Mol. Cell Res. 1843 2014 2432 2437
19. N. Jonckheere, N. Skrypek, J. Merlin, A.F. Dessein, P. Dumont, and E. Leteurtre The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways PLoS One 7 2012 e32232 10.1371/journal.pone.0032232
20. C. Mariette, M. Perrais, E. Leteurtre, N. Jonckheere, B. Hémon, and P. Pigny Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway Biochem. J. 377 2004 701 708 10.1042/BJ20031132
21. Q. Ye, Z. Yan, X. Liao, Y. Li, J. Yang, and J. Sun MUC1 induces metastasis in esophageal squamous cell carcinoma by upregulating matrix metalloproteinase 13 Lab. Investig. J. Tech. Methods Pathol. 91 2011 778 787 10.1038/labinvest.2011.12
22. H. Rajabi, R. Ahmad, C. Jin, M. Kosugi, M. Alam, and M.D. Joshi MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells J. Biol. Chem. 287 2012 10703 10713 10.1074/jbc.M111.323311
23. A.V. Kalra, and R.B. Campbell Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours Eur. J. Cancer 45 2009 164 173 10.1016/j.ejca.2008.10.008
24. A.V. Kalra, and R.B. Campbell Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain Br. J. Cancer 97 2007 910 918 10.1038/sj.bjc.6603972
25. R. Ahmad, M. Alam, H. Rajabi, and D. Kufe The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function J. Biol. Chem. 287 2012 20866 20875 10.1074/jbc.M112.357293